BioMarin Pharmaceutical Inc. Files 8-K on Financials

TL;DR

BioMarin dropped an 8-K detailing its financial condition and results. Check it for the latest numbers.

AI Summary

BioMarin Pharmaceutical Inc. filed an 8-K on April 24, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's performance. The principal executive offices are located at 770 Lindaro Street, San Rafael, California.

Why It Matters

This 8-K filing provides investors with crucial updates on BioMarin's financial health and operational results, impacting investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

• BioMarin Pharmaceutical Inc. (company) — Registrant
• April 24, 2024 (date) — Date of earliest event reported
• 770 Lindaro Street San Rafael California 94901 (address) — Principal Executive Offices
• 000-26727 (filing_id) — SEC File Number

FAQ

Key Financial Figures

• $0.001 B — ich registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market In

Filing Documents

• bmrn-20240424.htm (8-K) — 24KB
• earningsrelease-24apr24ex9.htm (EX-99.1) — 241KB
• bmrnlogoa01a.jpg (GRAPHIC) — 4KB
• 0001048477-24-000066.txt ( ) — 416KB
• bmrn-20240424.xsd (EX-101.SCH) — 2KB
• bmrn-20240424_lab.xml (EX-101.LAB) — 21KB
• bmrn-20240424_pre.xml (EX-101.PRE) — 12KB
• bmrn-20240424_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On April 24, 2024, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2024. The Company's press release issued on April 24, 2024 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of the Company dated April 24, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: April 24, 2024 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR